 | | parties | date | size | eqty | roy. |
| | Alseres Pharmaceuticals / Navidea Biopharmaceuticals | 01/2012 | | | |
| | Option to Altropane iodine-123 radiolabeled imaging agent for Parkinson's disease |
| | BioParadox / Fogarty Institute for Innovation | 02/2012 | | | |
| | Platelet-Cell Therapy for the treatment of cardiovascular disease |
| | Synthetic Genomics / Integrated DNA Technologies | 02/2012 | | | |
| | SGI technology to manufacture small synthetic gene products |
| | Threshold Pharmaceuticals / Merck | 02/2012 | $550.0 | | |
| | Co-development of TH-302 small molecule hypoxia-targeted compound for cancer worldwide, option to co-promote in the US |
| | Fred Hutchinson,Sangamo BioSciences / NIAID | 07/2011 | $19.5 | | |
| | Five-year grant to fund HIV research focused on HIV latency and including CCR5-negative autologous stem cell transplantation |
| | Insero Health / Yale | 02/2012 | | | |
| | Synthetic manufacturing process for huperzine natural product to treat epilepsy |
| | Insero Health / Harvard | 02/2012 | | | |
| | Patents for the use of huperzine to treat epilepsy and other indications |
| | OctoPlus / Ferring | 02/2012 | | | |
| | Formulation development and contract manufacturing for undisclosed compound |
| | Alize Pharma / EUSA Pharma | 02/2012 | | | |
| | ASPAREC recombinant pegylated Erwinia chrysanthemi-derived asparaginase to treat acute lymphoblastic leukemia |
| | UCB / Astellas Pharma | 01/2012 | | | |
| | Cimzia (certolizumab pegol) anti-TNF therapy for rheumatoid arthritis in Japan |